VivoSeq
Nephrology

Primary Membranous Nephropathy

8

Pipeline Programs↗

4

Active Trials↗

8

Companies Involved↗

Primary Membranous Nephropathy is an early-stage landscape with 8 programs across 8 companies. The most active players are AstraZeneca, Roche, Cerium Pharmaceuticals, Inc.. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2Roche logo

Roche

2 programs

Phase 3C

Cerium Pharmaceuticals, Inc.

1 program

Phase 3V

Veloxis Pharmaceuticals

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3K

Kenvue Brands

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

6 of 9 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody222%Protein / enzyme111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
Active, not recruiting·Roche logoRoche·Phase 3·NCT04629248·142 enrolled
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07571746·43 enrolled
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Preclinical·NCT07204275·176 enrolled
A Phase 3 Superiority Study Comparing the Safety and Efficacy of SNP-ACTH (1-39) Gel Compared to Rituximab and FDA Approved Biosimilars in Adults With Primary Membranous Nephropathy (PMN) in a Two-Phase Adaptive Trial Design
Recruiting·CCerium Pharmaceuticals, Inc.·Phase 3·NCT05696613·148 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)